CY1116646T1 - Αντικαρκινικη πρωτεϊνη συντηξης - Google Patents

Αντικαρκινικη πρωτεϊνη συντηξης

Info

Publication number
CY1116646T1
CY1116646T1 CY20151100743T CY151100743T CY1116646T1 CY 1116646 T1 CY1116646 T1 CY 1116646T1 CY 20151100743 T CY20151100743 T CY 20151100743T CY 151100743 T CY151100743 T CY 151100743T CY 1116646 T1 CY1116646 T1 CY 1116646T1
Authority
CY
Cyprus
Prior art keywords
fusion protein
sequence
region
terminus
cancer fusion
Prior art date
Application number
CY20151100743T
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Krzysztof Kazimierz Lemke
Sebastian Pawlak
Bartlomiej Zerek
Original Assignee
Adamed Sp. Z O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL393146A external-priority patent/PL393146A1/pl
Application filed by Adamed Sp. Z O.O. filed Critical Adamed Sp. Z O.O.
Publication of CY1116646T1 publication Critical patent/CY1116646T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Πρωτεΐνη σύντηξης η οποία αποτελείται από μία περιοχή (a) η οποία είναι λειτουργικό θραύσμα αλληλουχίας πρωτεΐνης hTRAIL, το οποίο θραύσμα ξεκινά με αμινοξύ σε θέση όχι χαμηλότερη από hTRAIL95, ή ομόλογο του εν λόγω λειτουργικού θραύσματος που έχει τουλάχιστον 70% ταυτότητα αλληλουχίας, και περιοχή (b) η οποία είναι αλληλουχία ανοσοδιεγερτικού πεπτιδίου τελεστή, όπου η αλληλουχία περιοχής (b) είναι προσαρτημένη στο C-άκρο ή Ν-άκρο της περιοχής (a). Η πρωτεΐνη σύντηξης μπορεί να χρησιμοποιηθεί για τη θεραπευτική αγωγή ασθενειών καρκίνου.
CY20151100743T 2010-12-03 2015-08-25 Αντικαρκινικη πρωτεϊνη συντηξης CY1116646T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL393146A PL393146A1 (pl) 2010-12-03 2010-12-03 Przeciwnowotworowe białko fuzyjne
PL39459711 2011-04-18
EP11790636.2A EP2646464B1 (en) 2010-12-03 2011-12-05 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
CY1116646T1 true CY1116646T1 (el) 2017-03-15

Family

ID=45065918

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100743T CY1116646T1 (el) 2010-12-03 2015-08-25 Αντικαρκινικη πρωτεϊνη συντηξης

Country Status (27)

Country Link
US (1) US9161991B2 (el)
EP (1) EP2646464B1 (el)
JP (1) JP5759557B2 (el)
KR (1) KR101952460B1 (el)
CN (1) CN103237808B (el)
AU (1) AU2011334868B2 (el)
BR (1) BR112013013548B8 (el)
CA (1) CA2814595C (el)
CY (1) CY1116646T1 (el)
DK (1) DK2646464T3 (el)
EA (1) EA024452B1 (el)
ES (1) ES2545895T3 (el)
HK (1) HK1186192A1 (el)
HR (1) HRP20150664T1 (el)
HU (1) HUE027068T2 (el)
IL (1) IL226207A (el)
ME (1) ME02224B (el)
MX (1) MX337436B (el)
NZ (1) NZ609216A (el)
PL (1) PL2646464T3 (el)
PT (1) PT2646464E (el)
RS (1) RS54057B1 (el)
SG (2) SG10201509676UA (el)
SI (1) SI2646464T1 (el)
SM (1) SMT201500203B (el)
WO (1) WO2012072815A1 (el)
ZA (1) ZA201303449B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL219845B1 (pl) * 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP2670426B1 (en) * 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
EP2877572B1 (en) 2012-07-24 2018-11-28 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
CN106632682A (zh) * 2015-08-04 2017-05-10 清华大学 融合蛋白ifn-elp及其应用
JP2022529943A (ja) 2019-04-15 2022-06-27 クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
MX2022012592A (es) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Construcciones de citocinas activables y composiciones y metodos relacionados.
TW202304958A (zh) 2021-03-16 2023-02-01 美商Ｃｙｔｏｍｘ生物製藥公司 經遮蔽之可活化之細胞介素構築體及相關之組成物及方法
KR20230169700A (ko) 2022-06-09 2023-12-18 제주대학교 산학협력단 Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240068191A (ko) 2022-11-10 2024-05-17 제주대학교 산학협력단 리모닌을 유효성분으로 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240072614A (ko) 2022-11-17 2024-05-24 제주대학교 산학협력단 감귤 무봉 추출물을 유효성분으로 포함하는 탈모증상의 예방 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
IL149261A0 (en) 1995-06-29 2002-11-10 Immunex Corp Antibodies that bind a tnf related apoptosis inducing ligand (trail) peptide
DE60105647T2 (de) * 2000-06-09 2005-09-22 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Pegylation von linker verbessert die antitumor-aktivität und verringert die toxizität von immunkonjugaten
DE60141992D1 (el) * 2000-09-05 2010-06-10 Biosight Ltd
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
ATE501256T1 (de) 2003-11-03 2011-03-15 Beijing Sunbio Biotech Co Ltd Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
WO2007022157A2 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CA2692802C (en) * 2007-07-10 2017-05-30 Oliver Hill Tnf superfamily collectin fusion proteins
CA3128656A1 (en) * 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

Also Published As

Publication number Publication date
AU2011334868A1 (en) 2013-05-02
SMT201500203B (it) 2015-10-30
ZA201303449B (en) 2014-01-29
SI2646464T1 (sl) 2015-07-31
MX337436B (es) 2016-03-03
US9161991B2 (en) 2015-10-20
KR101952460B1 (ko) 2019-02-27
WO2012072815A1 (en) 2012-06-07
DK2646464T3 (en) 2015-08-24
EP2646464B1 (en) 2015-06-03
CA2814595C (en) 2020-06-16
HUE027068T2 (en) 2016-08-29
ME02224B (me) 2016-02-20
BR112013013548A2 (pt) 2016-10-11
AU2011334868B2 (en) 2015-01-22
BR112013013548B1 (pt) 2022-03-29
US20130251676A1 (en) 2013-09-26
IL226207A (en) 2016-07-31
HK1186192A1 (en) 2014-03-07
IL226207A0 (en) 2013-07-31
RS54057B1 (en) 2015-10-30
BR112013013548B8 (pt) 2022-11-08
EP2646464A1 (en) 2013-10-09
EA201390820A1 (ru) 2013-12-30
ES2545895T3 (es) 2015-09-16
CA2814595A1 (en) 2012-06-07
NZ609216A (en) 2014-05-30
HRP20150664T1 (hr) 2015-07-31
MX2013006213A (es) 2013-07-29
JP5759557B2 (ja) 2015-08-05
SG10201509676UA (en) 2015-12-30
SG189370A1 (en) 2013-05-31
KR20130122764A (ko) 2013-11-08
CN103237808A (zh) 2013-08-07
CN103237808B (zh) 2016-02-24
PL2646464T3 (pl) 2015-10-30
JP2014502158A (ja) 2014-01-30
PT2646464E (pt) 2015-10-05
EA024452B1 (ru) 2016-09-30

Similar Documents

Publication Publication Date Title
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1122178T1 (el) Πολυπεπτιδια
CY1116099T1 (el) Πρωτεϊνη συντηξης κατα του καρκινου
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
PH12014501083A1 (en) Anticancer fusion protein
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
CY1121953T1 (el) Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων
CY1122079T1 (el) Πρωτεϊνες επαναληψης διπεπτιδιου ως θεραπευτικος στοχος στις νευροεκφυλιστικες νοσους με επεκταση επαναληψης των εξανουκλεοτιδιων
CY1121687T1 (el) Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
CY1118200T1 (el) Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης
CY1120352T1 (el) Ανοσοθεραπεια βασισμενη στη 2,3 διοξυγοναση της ινδολεαμινης
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
CY1119737T1 (el) Νεες συνθεσεις και μεθοδοι
CY1115316T1 (el) Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
CY1120212T1 (el) Πεπτιδια
EA201391546A1 (ru) Противораковый слитый белок
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины